Regulation of Organized Intestinal Lymphoid Tissues by TRANCE/RANKL

TRANCE/RANKL 对有组织肠淋巴组织的调节

基本信息

  • 批准号:
    8432109
  • 负责人:
  • 金额:
    $ 3.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-04-01 至 2013-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Peyer's patches (PP) and isolated lymphoid follicles (ILF) are organized mucosal lymphoid tissues in the intestine that serve as inductive sites for immune responses to antigens in the intestinal lumen. We discovered that RANKL (also known as TRANCE and TNFSF11), a member of the TNF superfamily previously shown to have obligatory roles in the development of lymph nodes, the differentiation of medullary thymic epithelial cells, the differentiation of osteoclasts, and mammary gland lactation, is also present on stromal cells in ILF and PP. These RANKL-expressing stromal cells are concentrated in the subepithelial dome area in close apposition to the follicle-associated epithelium. PP in RANKL null mice were previously characterized as smaller than those in wild type mice, but additional phenotypic abnormalities were not reported. We find that the PP of RANKL null mice have a large deficit in the development of M cells, specialized epithelial cells capable of rapid uptake and delivery of particulate antigens into antigen-presenting cells (APC) found within and beneath the epithelium. On average, the small intestine of RANKL null mice has 74-fold fewer M cells detected by staining with the UEA-1 lectin than wild type control mice. The loss of UEA-1+ M cells in RANKL null mice correlates with a nearly complete loss in the ability of RANKL null PP to translocate 200 nm diameter fluorescent beads from the intestinal lumen into APC located in the PP subepithelial dome. M cell development in RANKL null mice can be rescued by treatment with recombinant RANKL for 7 days. Treatment of wild type mice with neutralizing anti- RANKL antibodies reproduces the loss of M cells observed in RANKL null mice. The central hypothesis guiding the proposed experiments is that RANKL acting through its receptor RANK on epithelial cells is a critical signaling pathway required for normal M cell differentiation and function. While M cells were first described in the rabbit appendix over 30 years ago and are known to have a central role in uptake of particulate antigens in mucosal tissues while also being exploited as a portal of entry by pathogens, the details of the histogenesis of these cells have largely remained a mystery. The first aim of the proposal is to determine whether stromal cells are the major source of RANKL involved in induction of M cell differentiation in the FAE and whether the action of RANKL to induce M cell differentiation is restricted to stem cells in the dome-associated crypts. The second aim is to determine whether the functional activity of M cells can be altered by manipulation of RANKL- RANK signaling with exogenous RANKL and neutralizing anti-RANKL antibody. The third aim is to determine how local expression of the osteoprotegerin (OPG) soluble decoy receptor and RANKL-induced effects on intestinal DC and macrophages influence the effects of stromal cell RANKL on RANK-expressing enterocytes. Mechanistic insights into how the RANKL-RANK pathway supports pathways of antigen handling by the gut immune system that foster development of tolerance of antigens normally encountered in the gut lumen may be useful in developing oral vaccination strategies and in the treatment of human inflammatory bowel disease. PUBLIC HEALTH RELEVANCE: The goal of this research is to identify the role of a protein known as RANKL (RANK ligand) and RANK (its receptor) in the establishment and normal functioning of organized lymphocyte containing structures in the small and large intestine. These lymphoid structures such as Peyer's patches normally contribute to protecting the host from pathogens and preventing inappropriate immune responses to antigens normally encountered in the intestinal microenvironment. These studies are expected to contribute to existing knowledge of how specific imbalances in the intestinal immune system can lead to various forms of human inflammatory bowel disease.
描述(由申请方提供):派尔集合淋巴结(PP)和分离淋巴滤泡(ILF)是肠道中的组织化粘膜淋巴组织,作为肠腔中抗原免疫应答的诱导部位。我们发现,RANKL(也称为TRANCE和TNFSF 11)是TNF超家族的一个成员,以前被证明在淋巴结发育、胸腺髓质上皮细胞分化、破骨细胞分化和乳腺泌乳中具有强制性作用,也存在于ILF和PP的基质细胞上。这些RANKL表达基质细胞集中在上皮下圆顶区域,与卵泡相关上皮紧密贴壁。先前将RANKL敲除小鼠的PP表征为小于野生型小鼠的PP,但未报告其他表型异常。我们发现RANKL基因敲除小鼠的PP在M细胞发育方面存在较大缺陷,M细胞是能够快速摄取颗粒抗原并将其递送至上皮内和上皮下发现的抗原呈递细胞(APC)的特化上皮细胞。平均而言,通过UEA-1凝集素染色检测到的RANKL敲除小鼠小肠中的M细胞比野生型对照小鼠少74倍。RANKL敲除小鼠中UEA-1+ M细胞的丢失与RANKL敲除PP将直径200 nm的荧光珠从肠腔转运至位于PP上皮下圆顶中的APC的能力几乎完全丧失相关。RANKL缺失小鼠中的M细胞发育可通过重组RANKL处理7天来挽救。用中和抗RANKL抗体处理野生型小鼠重现了在RANKL缺失小鼠中观察到的M细胞损失。指导拟议实验的中心假设是RANKL通过其受体RANK作用于上皮细胞,是正常M细胞分化和功能所需的关键信号传导途径。虽然M细胞在30多年前首次在兔阑尾中被描述,并且已知在粘膜组织中颗粒抗原的摄取中具有核心作用,同时也被病原体用作入口,但这些细胞的组织发生的细节在很大程度上仍然是一个谜。该提案的第一个目的是确定基质细胞是否是参与FAE中M细胞分化诱导的RANKL的主要来源,以及RANKL诱导M细胞分化的作用是否仅限于圆顶相关隐窝中的干细胞。第二个目的是确定M细胞的功能活性是否可以通过用外源性RANKL和中和抗RANKL抗体操纵RANKL- RANK信号传导来改变。第三个目的是确定骨保护素(OPG)可溶性诱饵受体的局部表达和RANKL对肠DC和巨噬细胞的诱导作用如何影响基质细胞RANKL对表达RANK的肠细胞的作用。RANKL-RANK通路如何支持肠道免疫系统处理抗原的途径,促进肠腔中通常遇到的抗原耐受性的发展,这一机制的见解可能有助于开发口服疫苗接种策略和治疗人类炎症性肠病。 公共卫生相关性:本研究的目的是确定一种称为RANKL(RANK配体)和RANK(其受体)的蛋白质在小肠和大肠中含有组织化淋巴细胞的结构的建立和正常功能中的作用。这些淋巴样结构如派尔集合淋巴结通常有助于保护宿主免受病原体的侵害,并防止对肠道微环境中通常遇到的抗原的不适当的免疫应答。这些研究预计将有助于现有的知识如何在肠道免疫系统的特定失衡可能导致各种形式的人类炎症性肠病。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Identification of novel genes selectively expressed in the follicle-associated epithelium from the meta-analysis of transcriptomics data from multiple mouse cell and tissue populations.
Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium.
  • DOI:
    10.1038/mi.2013.30
  • 发表时间:
    2013-07
  • 期刊:
  • 影响因子:
    8
  • 作者:
  • 通讯作者:
M cell-depletion blocks oral prion disease pathogenesis.
  • DOI:
    10.1038/mi.2011.68
  • 发表时间:
    2012-03
  • 期刊:
  • 影响因子:
    8
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

IFOR R WILLIAMS其他文献

IFOR R WILLIAMS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('IFOR R WILLIAMS', 18)}}的其他基金

Mucosal Immunology Course & Symposium (MICS)
粘膜免疫学课程
  • 批准号:
    9195544
  • 财政年份:
    2016
  • 资助金额:
    $ 3.37万
  • 项目类别:
CCR6 Regulation of Intestinal T Lymphocyte Development
CCR6 对肠道 T 淋巴细胞发育的调节
  • 批准号:
    6875743
  • 财政年份:
    2004
  • 资助金额:
    $ 3.37万
  • 项目类别:
CCR6 Regulation of Intestinal T Lymphocyte Development
CCR6 对肠道 T 淋巴细胞发育的调节
  • 批准号:
    7216199
  • 财政年份:
    2004
  • 资助金额:
    $ 3.37万
  • 项目类别:
Regulation of Organized Intestinal Lymphoid Tissues by TRANCE/RANKL
TRANCE/RANKL 对有组织肠淋巴组织的调节
  • 批准号:
    7732048
  • 财政年份:
    2004
  • 资助金额:
    $ 3.37万
  • 项目类别:
Regulation of Organized Intestinal Lymphoid Tissues by TRANCE/RANKL
TRANCE/RANKL 对有组织肠淋巴组织的调节
  • 批准号:
    8137918
  • 财政年份:
    2004
  • 资助金额:
    $ 3.37万
  • 项目类别:
CCR6 Regulation of Intestinal T Lymphocyte Development
CCR6 对肠道 T 淋巴细胞发育的调节
  • 批准号:
    7035400
  • 财政年份:
    2004
  • 资助金额:
    $ 3.37万
  • 项目类别:
CCR6 Regulation of Intestinal T Lymphocyte Development
CCR6 对肠道 T 淋巴细胞发育的调节
  • 批准号:
    6775267
  • 财政年份:
    2004
  • 资助金额:
    $ 3.37万
  • 项目类别:
Regulation of Organized Intestinal Lymphoid Tissues by TRANCE/RANKL
TRANCE/RANKL 对有组织肠淋巴组织的调节
  • 批准号:
    7928053
  • 财政年份:
    2004
  • 资助金额:
    $ 3.37万
  • 项目类别:
Regulation of Organized Intestinal Lymphoid Tissues by TRANCE/RANKL
TRANCE/RANKL 对有组织肠淋巴组织的调节
  • 批准号:
    8325162
  • 财政年份:
    2004
  • 资助金额:
    $ 3.37万
  • 项目类别:
TREFOIL FACTORS AND ORAL MUCOSAL WOUND HEALING
三叶因子和口腔粘膜伤口愈合
  • 批准号:
    6100609
  • 财政年份:
    1999
  • 资助金额:
    $ 3.37万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 3.37万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 3.37万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 3.37万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.37万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 3.37万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 3.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 3.37万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 3.37万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 3.37万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 3.37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了